Glenmark Pharmaceuticals peers

Companies like Glenmark Pharmaceuticalslatest year

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

GLENMARK₹2,300.00

Glenmark Pharmaceuticals Ltd.

· Pharma & Health
₹ CrorePeersDRREDDYLUPINALKEMBIOCONMANKINDLAURUSLABSFORTISAUROPHARMAMcap ₹64,906 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
GLENMARK
FY26
DRREDDY
FY26
LUPIN
FY26
ALKEM
FY26
Peer
Average
Valuation — at last close
P/E47.66×26.49×◆ 16.90×26.34×23.24× +105%
P/B6.17×◆ 2.94×4.02×4.39×3.78× +63%
EV/EBITDA13.94×17.19×◆ 9.86×20.06×15.71× -11%
Market Cap₹64,906 Cr₹1.12L Cr₹90,192 Cr₹60,612 Cr₹87,437 Cr -26%
Growth
Revenue CAGR 3Y9.34%10.96%◆ 18.88%8.25%12.70% -26%
Revenue CAGR 5Y9.19%12.09%◆ 13.02%10.09%11.73% -22%
Net Income CAGR 3Y53.39%-2.66%◆ 128.70%32.67%52.90% +1%
Revenue YoY (latest Q)23.10%-1.48%◆ 32.04%10.95%13.84% +67%
Net Income YoY (latest Q)◆ 927.88%-31.69%16.01%-22.00%-12.56% +7488%
Profitability
EBITDA Margin26.92%19.15%◆ 31.53%20.43%23.70% +14%
Net Income Margin8.02%12.34%◆ 19.16%15.98%15.83% -49%
Return on Common Equity0.00%11.75%◆ 26.90%17.84%18.83% -100%
Return on Capital Employed◆ 33.87%11.30%32.38%17.59%20.42% +66%
Return on Assets7.58%7.73%◆ 15.85%12.19%11.92% -36%
Credit & Quality
Total Debt/Equity◆ 0.00×0.16×0.26×0.11×0.18× -100%
Interest Coverage◆ 19.16×11.76×17.12×16.32×15.07× +27%
Scale — latest FY
Revenue / Total Income₹16,983 Cr₹33,700 Cr₹27,958 Cr₹14,712 Cr₹25,457 Cr -33%
Net Income₹1,362 Cr₹4,158 Cr₹5,355 Cr₹2,351 Cr₹3,955 Cr -66%
Total Assets₹19,908 Cr₹58,123 Cr₹38,365 Cr₹20,873 Cr₹39,120 Cr -49%
EPS₹48.26₹50.41₹116.75₹192.51₹119.89 -60%
Book Value per Share₹372.51₹453.79₹490.99₹1,156.01₹700.26 -47%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.